DTIL
NASDAQPrecision BioSciences Inc.
Price$7.04+2.51 (+55.41%)
2026-03-052026-06-08
News · 26 weeks61+89%
2025-12-142026-06-07
Mix3690d
- Insider14(39%)
- Other11(31%)
- SEC Filings10(28%)
- Earnings1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Brown Melinda4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Frankel Stanley4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Germano Geno J4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Pire Shari Lisa4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Buehler Kevin4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Chief Research Officer Smith J. Jefferson4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Kelly John Alexander4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel and Secretary Scimeca Dario4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Amoroso Michael4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- INSIDERDirector Buehler Kevin converted options into 21,000 shares, increasing direct ownership by 75% to 49,137 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Frankel Stanley converted options into 21,000 shares, increasing direct ownership by 108% to 40,478 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Brown Melinda converted options into 21,000 shares, increasing direct ownership by 90% to 44,346 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Pire Shari Lisa converted options into 21,000 shares, increasing direct ownership by 150% to 35,028 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Germano Geno J converted options into 21,000 shares, increasing direct ownership by 88% to 44,883 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- PRiECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE TrialFirst infant treated in the low-dose cohort achieved durable clinical response with sustained discontinuation of standard-of-care therapies, and no hyperammonemic events (HAEs) reported in the 18 months following administration of ECUR-506 Statistically significant reductions in the annualized rate of HAEs and hyperammonemic crises (HACs) observed in the completed low-dose cohort (n=3), with 57% (p =0.018) and 65% (p =0.011) reductions, respectively, in pre-dose to post-dose rates of events per person-year Data presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo t
- PRPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young as 2 years of age – – Greater efficacy with earlier intervention further differentiates PBGENE-DMD from microdystrophin approaches – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new preclinical data from its PBGENE-DMD pr
- PRiECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual MeetingPreliminary data from participants enrolled in three dose cohorts (n=7) demonstrate that 71% of participants experienced no hyperammonemic crises (HACs) following ECUR-506 treatment, as of the April 20, 2026 data cutoff date. HACs are defined as plasma ammonia levels above 100µmol/L with neurologic status change. Data from these cohorts also demonstrate approximately 52% reduction in the annualized rate of HACs following ECUR-506 administration. HACs are the most clinically significant neurometabolic manifestation of ornithine transcarbamylase (OTC) deficiency. Reducing or preventing these crises is a key treatment goal, clinically meaningful measure of patient benefit, and an im
- SECSEC Form 10-Q filed by Precision BioSciences Inc.10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PRPrecision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the first quarter 2026 and provide a business update on May 5, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more de
- PRPrecision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study- Arkansas Children's Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD - Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene editing treatment for Duchenne muscular dystrophy (DMD), is being evaluated in the Phase 1/2 FUNCTION-DMD study. PBGENE-DMD is Precision's wholly owned in vivo gene editing pr
- PRiECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual MeetingsiECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that clinical data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026 in Boston, and the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, taking place May 17-20, 2026 in Puerto Rico. The oral presentation at ASGCT will include preliminary data from study participants in the first three dose cohorts (n=7
- PRPrecision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual MeetingPrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. The accepted abstract highlights new data demonstrating compelling efficacy observed in early-juvenile mice supporting the potential benefit of earlier intervention with PBGENE-DMD in younger patient populations. These data build on previously shared u
DTIL FAQ
7 questionsWhat does Precision BioSciences Inc. do?
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin...Where does DTIL stock trade?
Precision BioSciences Inc. (DTIL) is listed on NASDAQ.What sector and industry is DTIL in?
Precision BioSciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Precision BioSciences Inc. go public?
Precision BioSciences Inc. (DTIL) completed its IPO in 2019.What are analysts saying about DTIL?
Precision BioSciences Inc. has had 5 recent analyst actions on file. The most recent action was from BMO Capital Markets: Outperform with a $3400.00 price target on 2025-01-10. Recent price targets range from $700.00 to $3400.00.What companies are similar to DTIL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DTIL side-by-side with any of them on Quantisnow.How can I track DTIL on Quantisnow?
Quantisnow aggregates Precision BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DTIL to receive live email and push alerts on every new disclosure.